Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

The global radiopharmaceutical market size is calculated at USD 7.32 billion in 2025 and is expected to reach around USD ...

Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced the promotion of Prashant Nambiar, DVM, PhD, MBA, as Chief Scientific Officer and appointment of Ethan Cash as ...

Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory ...

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.